BioStem Technologies (BSEM) to Release Earnings on Monday

Key Points

• BioStem Technologies is set to release its Q4 2025 results on Monday, April 13; analysts expect earnings of $0.02 per share and revenue of $55.20 million.
• The stock opened at $4.57, trades in a 52-week range of $3.09–$15.74, has a market cap of $77.05 million, and a negative P/E of -10.77.
• Zacks Research recently upgraded BioStem to a Hold, and MarketBeat shows a consensus Hold rating based on one analyst.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) is projected to post its Q4 2025 resultson Monday, April 13th. Analysts expect BioStem Technologies to post earnings of $0.02 per share and revenue of $55.20 million for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

BioStem Technologies Price Performance

Shares of OTCMKTS:BSEM opened at $4.57 on Monday. BioStem Technologies has a 52 week low of $3.09 and a 52 week high of $15.74. The stock has a market capitalization of $77.05 million and a P/E ratio of -10.77. The firm has a fifty day simple moving average of $5.59 and a two-hundred day simple moving average of $4.86.

Analyst Ratings Changes

Separately, Zacks Research upgraded BioStem Technologies to a "hold" rating in a research report on Wednesday, March 18th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, BioStem Technologies currently has a consensus rating of "Hold".

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.